ArticleEuropean journal of clinical investigation2025
Anti-neutrophil cytoplasmic antibodies associated interstitial pneumonia: A possible new clinical entity.
Article in European journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Reply.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Interstitial lung disease in ANCA-associated vasculitis: comment on the article by Chalkia et al.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Anti-neutrophil cytoplasmic antibodies associated interstitial pneumonia: A possible new clinical entity.European journal of clinical investigation · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-neutrophil cytoplasmic antibodies (ANCA), a hallmark of systemic vasculitis (SV), have been reported in patients with idiopathic interstitial pneumonia (IIP). However, the clinical significance of ANCA in IIP remains unclear.
methodsWe retrospectively studied 101 IP patients diagnosed by pneumologists as idiopathic interstitial pneumonia (IIP,64) and IP with autoimmune features (IPAF,37). ANCA, anti-myeloperoxidase and anti-proteinase-3 were tested by immunofluorescence and ELISA. Chest HRCT patterns, pulmonary function tests (PFTs) and the evolution to SV during a 12-month follow-up were assessed. Multivariable regression analysis was performed to assess the association of baseline covariates with SV. The proximity of patients with close characteristics was investigated by cluster analysis.
resultsTwenty-one patients (20.8%) were ANCA+, similarly distributed between IPAF and IIP. ANCA+ patients were more likely to have NSIP (p = .02) and bronchiectasis (p = .02) on HRCT, less impaired 6MWD (p = .02), higher CRP (p = .02) and more arthralgias (p < .001) than ANCA- patients. During follow-up, 9 (43%) p-ANCA+ patients, but no ANCA- patients, developed SV (p = .001). p-ANCA+ IP had 26.3 OR (95% CI 3.20-36.8) to evolve to SV within 12 months (p < .0001). Cluster analysis identified one group of 25 patients with significantly higher baseline NSIP (88%), p-ANCA+ (48%), arthralgias (32%), and SV (24%) at 12 months. Nevertheless, 12 p-ANCA+ IP patients never developed SV.
conclusionsANCA+ IP patients had a high risk of developing SV and need close monitoring and prompt immunotherapy. ANCA+ IP patients not evolving to SV had a diagnosis of IIP or IPAF. These patients need longer observational studies to investigate if they represent a distinct ILD entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.